Focinvez Generic: When Will Generic Fosaprepitant Dimeglumine Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Focinvez Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? January 2039 About 12.5 years away Why then?
- Has the FDA approved a generic? June 2016 9 companies approved
- When does the last patent end? January 2039 2 patents listed with the FDA
- Can you buy a generic today? Yes 13 companies list one
It already is. A generic fosaprepitant dimeglumine is listed for sale by 13 companies, so ask your pharmacy whether it can fill your prescription with one.
Why January 2039?
It is when Focinvez’s patents 11,065,265 and 12,042,504 end. They cover the product’s formulation, and once they end, generics can go on sale as soon as the FDA approves them. We rate it toss-up: still unsettled. Just as likely to slip as to hold.
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Focinvez, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Focinvez by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Toss-up Still unsettled. Just as likely to slip as to hold.
- Price competition
- None filed yet No filers on record
- Brand sales
- $38M a yearSmaller seller
- FDA approved 2023 August 2023 FDA Orange Book
- Patents listed 2 last runs to January 2039 FDA Orange Book
- Generics FDA-approved 9 companies, the first approved June 2016 FDA Orange Book
- Medicare Part D spent $59.9K in 2025, for 22 people CMS Part D Spending by Drug
- Medicaid prescriptions 1,925 in the last four reported quarters, $689.1K CMS Medicaid drug utilization, to Q1 2026
Focinvez’s Road to a Generic
Focinvez has had the market to itself since the FDA approved it in August 2023 (Steriscience Pte Ltd). Its 2 listed patents run to January 2039.
The first generic of Focinvez is expected in January 2039.
Why that month: patents 11,065,265 and 12,042,504, on the product’s formulation, end then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Focinvez Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Focinvez’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patents 11,065,265 and 12,042,504, which end in January 2039, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 11,065,265 Sets the expected month of generic availability | The product’s formulation | January 2039 | Active |
| 12,042,504 Sets the expected month of generic availability | The product’s formulation | January 2039 | Active |
Source: FDA Orange Book, application 216686. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Fosaprepitant Dimeglumine
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No application count is on record for Focinvez, but the FDA has already approved 9 companies (step 2), and every approval starts with an application.
Approved by the FDA
The FDA has approved generic versions from 9 companies, the first in June 2016. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
For Sale in Pharmacies
Yes. A generic fosaprepitant dimeglumine is listed for sale by 13 companies. Ask your pharmacy whether it can fill your prescription with it.
Athenex Pharmaceutical Division, LLC., AuroMedics Pharma LLC, Avenacy, LLC, Baxter Healthcare Corporation, BluePoint Laboratories, Camber Pharmaceuticals, Inc. and 7 more
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Fresenius Kabi USA LLC | June 2016 | EQ 150MG BASE/VIAL | AP |
| Be Pharmaceuticals AG | September 2019 | EQ 150MG BASE/VIAL | AP |
| Msn Laboratories Private Ltd | September 2019 | EQ 150MG BASE/VIAL | AP |
| Mylan Laboratories Ltd | September 2019 | EQ 115MG BASE/VIAL, EQ 150MG BASE/VIAL | AP |
| Qilu Pharmaceutical Hainan Co Ltd | September 2020 | EQ 150MG BASE/VIAL | AP |
| Dr Reddys Laboratories Ltd | December 2020 | EQ 150MG BASE/VIAL | AP |
| Eugia Pharma Specialities Ltd | January 2021 | EQ 150MG BASE/VIAL | AP |
| Chia Tai Tianqing Pharmaceutical Group Co Ltd | March 2021 | EQ 150MG BASE/VIAL | AP |
| Aspiro Pharma Ltd | July 2021 | EQ 150MG BASE/VIAL | AP |
| Apotex Inc discontinued | September 2019 | EQ 150MG BASE/VIAL | – |
| Baxter Healthcare Corp discontinued | September 2019 | EQ 150MG BASE/VIAL | – |
| Geneyork Pharmaceuticals Group LLC discontinued | September 2019 | EQ 150MG BASE/VIAL | – |
| Lupin Ltd discontinued | September 2019 | EQ 150MG BASE/VIAL | – |
| Chartwell Rx Sciences LLC discontinued | August 2020 | EQ 150MG BASE/VIAL | – |
| Accord Healthcare Inc discontinued | August 2020 | EQ 150MG BASE/VIAL | – |
| Caplin Steriles Ltd discontinued | December 2020 | EQ 150MG BASE/VIAL | – |
| Praxgen Pharmaceuticals LLC discontinued | October 2021 | EQ 150MG BASE/VIAL | – |
| Piramal Critical Care Inc discontinued | May 2023 | EQ 150MG BASE/VIAL | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Focinvez Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Focinvez, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Focinvez
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Focinvez, before manufacturer rebates.
- $14.7K
- January to March 2026, the latest CMS has posted
For 11 people, about $566 per prescription fill - $59.9K
- 2025, the whole year
For 22 people, about $544 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $14,728 | 11 | $566.45 |
| 2025 | $59,887 | 22 | $544.42 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Focinvez only, so no generic is counted in it. What CMS says it is used for: Fosaprepitant is used with other medications to help prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). Fosaprepitant works by blocking one of the body's natural substances (substance P/neurokinin 1) that causes vomiting.
Medicaid Prescriptions by Quarter
1,925 prescriptions in the four quarters to Q1 2026, $689.1K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 659 | $200,851 |
| Q4 2025 | 580 | $192,034 |
| Q3 2025 | 429 | $169,016 |
| Q2 2025 | 257 | $127,198 |
| Q1 2025 | 387 | $247,060 |
Source: CMS Medicaid State Drug Utilization Data, over Focinvez’s own package codes.
Focinvez Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 150MG BASE/50ML (EQ 3MG BASE/ML) | Solution | Intravenous | August 2023 | Prescription reference product |
Source: FDA Orange Book, Steriscience Pte Ltd. Listed for sale today by Spes Pharmaceuticals Inc., Amneal Pharmaceuticals LLC and Steriscience Specialties Private Limited (FDA NDC Directory).
Focinvez NDC Codes and Packages
Each Focinvez package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 82243-1001-01 | 150 mg/50mL injection | vial of 50 mL | Spes Pharmaceuticals Inc. |
| 70121-2631-01 | FOSAPREPITANT DIMEGLUMINE 150 mg/50mL injection | vial of 50 mL | Amneal Pharmaceuticals LLC |
| 82449-0231-01 | FOSAPREPITANT DIMEGLUMINE 150 mg/50mL injection | vial of 50 mL | Steriscience Specialties Private Limited |
Source: the FDA NDC Directory, current listings only. Only packages sold under Focinvez’s own FDA approval (NDA 216686) are listed, never a generic. Some codes belong to companies that repackage Focinvez: it is the same medicine in a different package.
What a Generic Focinvez Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Focinvez
Is there a generic for Focinvez right now?
Yes. The FDA NDC Directory lists a generic fosaprepitant dimeglumine from 13 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Focinvez go generic?
It already has. The FDA NDC Directory lists a generic fosaprepitant dimeglumine from 13 companies, so ask your pharmacy whether it can fill your prescription with one.
Will generic fosaprepitant dimeglumine be the same as Focinvez?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. The FDA has already approved 9 companies to make a generic, and how many of them launch decides how far the price falls.
Has the FDA approved a generic Focinvez?
Yes. The FDA Orange Book lists approved generic versions from 9 companies, the first approved in June 2016: Fresenius Kabi USA LLC, Be Pharmaceuticals AG, Msn Laboratories Private Ltd, Mylan Laboratories Ltd and 5 more. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
When does the Focinvez patent expire?
The FDA Orange Book lists 2 patents for Focinvez; the last runs to January 2039. The one behind the expected month is patents 11,065,265 and 12,042,504, which end in January 2039. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (January 2039) weighs all of that.
Changes to This Projection
- First generic expected January 2039 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- InvokanaCanagliflozin2027 to 2028
- VitektaElvitegravirFebruary 2027
- OdefseyEmtricitabine, Rilpivirine Hydrochloride, and Tenofovir Alafenamide FumarateJanuary 2032
- SeysaraSarecycline HydrochlorideFebruary 2033
- Drizalma SprinkleDuloxetine HydrochlorideApril 2037
- AmeluzAminolevulinic Acid HydrochlorideDecember 2043
About Focinvez
- Generic name fosaprepitant dimeglumine
- How it is taken Into a vein (IV)
- Company Steriscience Pte Ltd
- More drugs Brand-name drugs starting with F
- Have a question? A pharmacist answers, free. Ask about Focinvez
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.